Treatment preferences for biologicals in psoriasis: experienced patients appreciate sustainability.

about

Treatment preferences for biologicals in psoriasis: experienced patients appreciate sustainability.

Item

http://www.wikidata.org/entity/Q42646805

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Treatment preferences for biol ...... nts appreciate sustainability.

@en

Treatment preferences for biol ...... nts appreciate sustainability.

@nl

type

Item

label

Treatment preferences for biol ...... nts appreciate sustainability.

@en

Treatment preferences for biol ...... nts appreciate sustainability.

@nl

prefLabel

Treatment preferences for biol ...... nts appreciate sustainability.

@en

Treatment preferences for biol ...... nts appreciate sustainability.

@nl

P1476

Treatment preferences for biol ...... nts appreciate sustainability.

@en

P2093

Astrid Schmieder

http://www.w3.org/2001/XMLSchema#string

Christian Kromer

http://www.w3.org/2001/XMLSchema#string

Diana Sonntag

http://www.w3.org/2001/XMLSchema#string

Marthe-Lisa Schaarschmidt

http://www.w3.org/2001/XMLSchema#string

Raphael Herr

http://www.w3.org/2001/XMLSchema#string

Wiebke K Peitsch

http://www.w3.org/2001/XMLSchema#string

P2860

Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease

Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011.

Elicitation and use of patients' preferences in the treatment of psoriasis: a systematic review.

European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey.

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.

Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice

Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment.

P304

189-200

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/DDG.12919

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28214326

http://www.w3.org/2001/XMLSchema#string